Literature DB >> 28980266

Mendelian Randomization.

Sandeep Grover1, Fabiola Del Greco M2, Catherine M Stein3, Andreas Ziegler4.   

Abstract

Confounding and reverse causality have prevented us from drawing meaningful clinical interpretation even in well-powered observational studies. Confounding may be attributed to our inability to randomize the exposure variable in observational studies. Mendelian randomization (MR) is one approach to overcome confounding. It utilizes one or more genetic polymorphisms as a proxy for the exposure variable of interest. Polymorphisms are randomly distributed in a population, they are static throughout an individual's lifetime, and may thus help in inferring directionality in exposure-outcome associations. Genome-wide association studies (GWAS) or meta-analyses of GWAS are characterized by large sample sizes and the availability of many single nucleotide polymorphisms (SNPs), making GWAS-based MR an attractive approach. GWAS-based MR comes with specific challenges, including multiple causality. Despite shortcomings, it still remains one of the most powerful techniques for inferring causality.With MR still an evolving concept with complex statistical challenges, the literature is relatively scarce in terms of providing working examples incorporating real datasets. In this chapter, we provide a step-by-step guide for causal inference based on the principles of MR with a real dataset using both individual and summary data from unrelated individuals. We suggest best possible practices and give recommendations based on the current literature.

Keywords:  Causal inference; Genome-wide association study; Individual data; Instrumental variable; Mendelian randomization; Observational epidemiology; Pleiotropy; Reverse causation; Summary data; Unobserved confounding

Mesh:

Year:  2017        PMID: 28980266     DOI: 10.1007/978-1-4939-7274-6_29

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  19 in total

Review 1.  Genetic Variation and Response to Neurocritical Illness: a Powerful Approach to Identify Novel Pathophysiological Mechanisms and Therapeutic Targets.

Authors:  Julián N Acosta; Stacy C Brown; Guido J Falcone
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

2.  Performing post-genome-wide association study analysis: overview, challenges and recommendations.

Authors:  Yagoub Adam; Chaimae Samtal; Jean-Tristan Brandenburg; Oluwadamilare Falola; Ezekiel Adebiyi
Journal:  F1000Res       Date:  2021-10-04

Review 3.  Recent innovations and in-depth aspects of post-genome wide association study (Post-GWAS) to understand the genetic basis of complex phenotypes.

Authors:  Zahra Mortezaei; Mahmood Tavallaei
Journal:  Heredity (Edinb)       Date:  2021-10-23       Impact factor: 3.821

Review 4.  Stroke Genetics: Turning Discoveries into Clinical Applications.

Authors:  Martin Dichgans; Nathalie Beaufort; Stephanie Debette; Christopher D Anderson
Journal:  Stroke       Date:  2021-08-17       Impact factor: 10.170

5.  Genetically Determined Smoking Behavior and Risk of Nontraumatic Subarachnoid Hemorrhage.

Authors:  Julián N Acosta; Natalia Szejko; Cameron P Both; Kevin Vanent; Rommell B Noche; Thomas M Gill; Charles C Matouk; Kevin N Sheth; Murat Gunel; Guido J Falcone
Journal:  Stroke       Date:  2021-01-14       Impact factor: 7.914

6.  White Matter and Alzheimer's Disease: A Bidirectional Mendelian Randomization Study.

Authors:  Yaqing Li; Jiaxin Zheng; Tian Li; Junjian Zhang
Journal:  Neurol Ther       Date:  2022-05-03

7.  Presidential address: Six open questions to genetic epidemiologists.

Authors:  Inke R König
Journal:  Genet Epidemiol       Date:  2019-01-19       Impact factor: 2.135

8.  Mendelian randomization: Progressing towards understanding causality.

Authors:  Inke R König; Fabiola M Del Greco
Journal:  Ann Neurol       Date:  2018-08-25       Impact factor: 10.422

9.  Evaluating the current state of Mendelian randomization studies: a protocol for a systematic review on methodological and clinical aspects using neurodegenerative disorders as outcome.

Authors:  Sandeep Grover; Fabiola Del Greco M; Inke R König
Journal:  Syst Rev       Date:  2018-09-24

10.  Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay.

Authors:  Liu Shi; Sarah Westwood; Alison L Baird; Laura Winchester; Valerija Dobricic; Fabian Kilpert; Shengjun Hong; Andre Franke; Abdul Hye; Nicholas J Ashton; Angharad R Morgan; Isabelle Bos; Stephanie J B Vos; Noel J Buckley; Mara Ten Kate; Philip Scheltens; Rik Vandenberghe; Silvy Gabel; Karen Meersmans; Sebastiaan Engelborghs; Ellen E De Roeck; Kristel Sleegers; Giovanni B Frisoni; Olivier Blin; Jill C Richardson; Régis Bordet; José L Molinuevo; Lorena Rami; Anders Wallin; Petronella Kettunen; Magda Tsolaki; Frans Verhey; Alberto Lleó; Daniel Alcolea; Julius Popp; Gwendoline Peyratout; Pablo Martinez-Lage; Mikel Tainta; Peter Johannsen; Charlotte E Teunissen; Yvonne Freund-Levi; Lutz Frölich; Cristina Legido-Quigley; Frederik Barkhof; Kaj Blennow; Henrik Zetterberg; Susan Baker; B Paul Morgan; Johannes Streffer; Pieter Jelle Visser; Lars Bertram; Simon Lovestone; Alejo J Nevado-Holgado
Journal:  Alzheimers Dement       Date:  2019-09-05       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.